Novabiotics, Taro Ink Alliance for Phase IIb-Ready Antifungal
LONDON – Novabiotics Ltd. rejected a new round of private funding in favor of an exclusive licensing deal with Taro Pharmaceuticals North America Inc., for the co-development of its first-in-class antifungal peptide Novexatin, which is about to enter Phase IIb development in the treatment of nail infection onychomycosis.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter